GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (NAS:MESO) » Definitions » Accounts Payable & Accrued Expense for Financial Companies

MESO (Mesoblast) Accounts Payable & Accrued Expense for Financial Companies


View and export this data going back to 2009. Start your Free Trial

What is Mesoblast Accounts Payable & Accrued Expense for Financial Companies?

Accounts Payable & Accrued Expense for Financial Companies only applies to insurance companies.


Mesoblast Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (NAS:MESO) » Definitions » Accounts Payable & Accrued Expense for Financial Companies
Address
55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.